U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H12I3NO4
Molecular Weight 650.9735
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LIOTHYRONINE

SMILES

N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O

InChI

InChIKey=AUYYCJSJGJYCDS-LBPRGKRZSA-N
InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1

HIDE SMILES / InChI

Molecular Formula C15H12I3NO4
Molecular Weight 650.9735
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Liothyronine (CYTOMEL®) is a T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than its prohormone thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. The mechanisms by which thyroid hormones exert their physiologic action are not well understood. These hormones enhance oxygen consumption by most tissues of the body, increase the basal metabolic rate and the metabolism of carbohydrates, lipids, and proteins. Thus, they exert a profound influence on every organ system in the body and are of particular importance in the development of the central nervous system. Thyroid hormone drugs are indicated: as the replacement or supplemental therapy in patients with hypothyroidism of any etiology; as pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters; as diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.1 nM [Kd]
0.1 nM [Kd]
0.1 nM [Kd]
0.1 nM [Kd]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CYTOMEL
Primary
CYTOMEL
Diagnostic
CYTOMEL
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
346 ng/dL
50 μg 1 times / day multiple, oral
LIOTHYRONINE SODIUM plasma
Homo sapiens
404 ng/dL
50 μg 1 times / day multiple, oral
LIOTHYRONINE SODIUM plasma
Homo sapiens
342 ng/dL
50 μg 1 times / day multiple, oral
LIOTHYRONINE SODIUM plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
4740 ng × h/dL
50 μg 1 times / day multiple, oral
LIOTHYRONINE SODIUM plasma
Homo sapiens
13938 ng × h/dL
50 μg 1 times / day multiple, oral
LIOTHYRONINE SODIUM plasma
Homo sapiens
4926 ng × h/dL
50 μg 1 times / day multiple, oral
LIOTHYRONINE SODIUM plasma
Homo sapiens
12929 ng × h/dL
50 μg 1 times / day multiple, oral
LIOTHYRONINE SODIUM plasma
Homo sapiens
4370 ng × h/dL
50 μg 1 times / day multiple, oral
LIOTHYRONINE SODIUM plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
22.04 h
50 μg 1 times / day multiple, oral
LIOTHYRONINE SODIUM plasma
Homo sapiens

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
The relative affinity of the rat synaptosomes for various T3 analogs was measured by incubating [3H]T3 with increasing amounts of T3, D-T3, T4, TRIAC and rT3, The results were expressed as the molar ratio of the concentrations of T3 or analog needed to decreaseby 50% the binding of [3H]T3.
Substance Class Chemical
Record UNII
06LU7C9H1V
Record Status Validated (UNII)
Record Version